Siwen Sun
Dalian, 116023, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
Correction: RBM4 dictates ESCC cell fate switch from cellular senescence to glutamine-addiction survival through inhibiting LKB1-AMPK-axis.
Journal: Signal transduction and targeted therapy
Published: August 31, 2026
Redefining first-line standards: The role of next-generation HER2-Targeted therapies in HER2-positive metastatic breast cancer.
Journal: Biochimica et biophysica acta. Reviews on cancer
Published: January 17, 2026
Loss of DDX24 inhibits lung cancer progression by stimulating IKBKG splicing-mediated autophagy.
Journal: Theranostics
Published: August 16, 2024
mTOR inhibitor introduce disitamab vedotin (RC48-ADC) rechallenge microtubule-chemotherapy resistance in HER2-low MBC patients with PI3K mutation.
Journal: Frontiers in oncology
Published: October 10, 2023
RBMS1 Coordinates with the m6A Reader YTHDF1 to Promote NSCLC Metastasis through Stimulating S100P Translation.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: September 26, 2023
A Novel Clinical Prognostic Model for Breast Cancer Patients with Malignant Pleural Effusion: Avoiding Chemotherapy in Low-Risk Groups?
Journal: Cancer management and research
Published: March 09, 2023
Melatonin inhibits HCC progression through regulating the alternative splicing of NEMO.
Journal: Frontiers in pharmacology
Published: July 29, 2022
RBM4 dictates ESCC cell fate switch from cellular senescence to glutamine-addiction survival through inhibiting LKB1-AMPK-axis.
Journal: Signal transduction and targeted therapy
Published: July 10, 2022
A novel treatment strategy of HER2-targeted therapy in combination with Everolimus for HR+/HER2- advanced breast cancer patients with HER2 mutations.
Journal: Translational oncology
Published: February 12, 2022
Last Updated: 09/26/2026